The grant project is part of the company's ongoing effort to expand into pre-designed research tests for disease biomarkers and point-of-care diagnostics.
Direct-to-consumer genetic testing companies have based their products on what scientists have accomplished, but the caveat is that the science is still in its early days.
Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.
